BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25796589)

  • 1. A case of C3 glomerulonephritis successfully treated with eculizumab.
    Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
    Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
    Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
    Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
    Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab and recurrent C3 glomerulonephritis.
    Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
    Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
    J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
    Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
    J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crescentic acute glomerulonephritis with isolated C3 deposition: a case report and review of literature.
    Mao S; Xuan X; Sha Y; Zhao S; Zhang A; Huang S
    Int J Clin Exp Pathol; 2015; 8(2):1826-9. PubMed ID: 25973075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy.
    Oba Y; Mizuno H; Taneda S; Sawai T; Oda T; Ikuma D; Yamanouchi M; Suwabe T; Kono K; Kinowaki K; Ohashi K; Sawa N; Ubara Y
    CEN Case Rep; 2024 Apr; 13(2):110-116. PubMed ID: 37452997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 glomerulopathy.
    Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
    Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
    Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
    Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
    Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report.
    Perea-Ortega L; León-Fradejas M; Alonso-Titos J; Cabello-Díaz M; Toledo-Rojas R; Sola-Moyano E; Martín-Reyes G; López-Jiménez V; Burgos-Rodríguez D; Hernández-Marrero D
    Transplant Proc; 2015 Nov; 47(9):2669-71. PubMed ID: 26680069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases].
    He RJ; Xiao HJ; Wang SX; Guan N; Yao Y; Ding J
    Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):939-43. PubMed ID: 23324154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab for treatment of rapidly progressive C3 glomerulopathy.
    Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
    Kerns E; Rozansky D; Troxell ML
    Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab for dense deposit disease and C3 glomerulonephritis.
    Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
    Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.